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Abstract
Background: Line blot immunoassays (LIA) for myositis-specific (MSA) and myositis-associated (MAA)
autoantibodies have become commercially available. In the largest study of this kind, we evaluated the clinical
performance of a widely used LIA for MSAs and MAAs.
Methods: Adults tested for MSA/MAA by LIA at a tertiary myositis centre (January 2016–July 2018) were identified.
According to expert-defined diagnoses, true and false positive rates were calculated for strongly and weakly
positive autoantibody results within three cohorts: idiopathic inflammatory myopathy (IIM), connective tissue
disease (CTD) without myositis, and non-CTD/IIM. Factors associated with true positivity were determined.
Results: We analysed 342 cases. 67 (19.6%) had IIM, in whom 71 autoantibodies were detected (50 strong positives
[70.4%], 21 weak positives [29.6%]). Of the strong positives, 48/50 (96.0%; 19 MSAs, 29 MAAs) were deemed true
positives. Of the weak positives, 15/21 (71.4%; 3 MSAs, 12 MAAs) were deemed true positives.
In CTD without myositis cases (n = 120), 31/61 (51.0%; 5 MSAs, 26 MAAs) autoantibodies were strongly positive,
with 24/31 (77.4%; 0 MSAs, 24 MAAs) true positives. 30/61 (49.2%; 13 MSAs, 17 MAAs) were weakly positive, with
16/30 (53.3%; 0 MSAs, 16 MAAs) true positives. In non-CTD/IIM cases (n = 155), all 24 MSAs and 22 MAAs were false
positives; these results included 17 (37.0%; 7 MSAs, 10 MAAs) strong positives.
Individual autoantibody specificities were > 98.2 and > 97.5% for weakly and strongly positive results, respectively.
True positivity was associated with high pre-test for IIM (odds ratio 50.8, 95% CI 13.7–189.2, p < 0.001) and strong
positive (versus weak positive) results (4.4, 2.3–8.3, p < 0.001).
Conclusions: We demonstrated the high specificity of a myositis LIA in a clinical setting. However, a significant
burden of false positive results was evident in those with a low pre-test likelihood of IIM and for weakly positive
autoantibodies.
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Background
The idiopathic inflammatory myopathies (IIM) are het-
erogeneous multisystem autoimmune diseases often pre-
senting with skeletal muscle weakness, rash, arthritis,
and/or interstitial lung disease [1]. IIM subtypes include
immune-mediated necrotising myopathy (IMNM), spor-
adic inclusion-body myositis (IBM), overlap myositis
(OM), anti-synthetase syndrome (ASS), dermatomyositis
(DM) and polymyositis (PM) [1–5].
Approximately 2/3 of IIM patients have detectable
serum autoantibodies (Abs), termed myositis-specific
autoantibodies (MSA), which are unique to IIM and
usually mutually exclusive to one another, or myositis-
associated autoantibodies (MAA) which can occur in
other connective tissue diseases (CTD) [6–8]. MSA/
MAAs are gaining importance in IIM diagnosis, can cir-
cumvent the requirement for a muscle biopsy, and may
inform prognosis [9–18].
Line blot immunoassays (LIA) for MSA/MAA have
become commercially available, increasing the availabil-
ity of testing in clinical practice [19]. Literature suggests
LIA is an appropriate substitute to conventional immu-
noprecipitation for MSA/MAA testing, but only small
samples have been studied with variable accuracy dem-
onstrated [13, 19, 20].
In the largest study of its kind, we evaluated the diag-
nostic accuracy of a commercially available LIA for
MSA and MAA testing in a clinical setting and exam-
ined factors associated with true positive results.
Methods
Cases
We retrospectively identified patients tested with the
EUROLINE Inflammatory Myopathies 16 Ag (IgG) com-
mercial LIA (Euroimmun, Lubeck, Germany) from Janu-
ary 1st, 2016, to July 30th, 2018, at Salford Royal NHS
Foundation Trust (SRFT), United Kingdom. The search
was limited to patients being reviewed in tertiary IIM,
systemic sclerosis and neuromuscular outpatient clinics.
Patients without available clinical data were removed.
Where duplicate testing occurred, only the most recent
results were analysed.
This study was performed as part of a quality improve-
ment project evaluating LIA usage at SRFT. Case notes
and other data were reviewed retrospectively without al-
teration to patient management. Given this context, and
after consultation with the Health Research Authority
(via www.hra-decisiontools.org.uk) this study proceeded
without further requirement for ethical authorization.
Autoantibody testing
The studied LIA can detect 12 MSAs (anti-Mi2A, anti-
Mi2B, anti-TIF1γ, anti-MDA5, anti-NXP2, anti-SAE1,
anti-SRP, anti-Jo1, anti-PL7, anti-PL12, anti-EJ, anti-OJ)
and 4 MAAs (anti-Ku, anti-PM-Scl100, anti-PM-Scl75,
anti-Ro52). Laboratory testing was performed using the
scanner, software, and protocol provided by the manu-
facturer. Results were categorised as negative, weakly
positive, or strongly positive according to the signal in-
tensity measured digitally as per the manufacturer’s
specifications.
Clinical data collection methodology
Patient records were reviewed by 2 authors (FT and CR)
independently. Demographics, electromyography (EMG)
results, muscle biopsy results, and peak serum total cre-
atine kinase (CK) levels were collated. Indications for or-
dering the LIA (pre-test diagnoses) were categorised
retrospectively as “suspected IIM”, “CTD without evi-
dence of myositis”, or “myopathic syndromes with low
likelihood of IIM”. The final diagnosis made by the ex-
pert treating clinician was recorded and categorised
retrospectively as “IIM” (including overlap syndromes),
“CTD without myositis”, or “non-IIM/CTD”. Categorisa-
tion was agreed on between the authors (FT, CR), and a
third author was consulted in indeterminate cases (JBL
or HC). Diagnoses were verified through review of ex-
tensive clinical information reflecting several years of
care in each case. Research classification criteria were
not applied as by their nature these are restrictive and
would limit the real-world applicability of this study. In
addition, recent studies have demonstrated classification
criteria may not accurately reflect clinical diagnoses
made by expert clinicians [21].
Assay performance
Ab results were reviewed and categorised as true or false
positive according to the available clinical information.
True positive MSAs were defined as those in patients di-
agnosed with IIM with the phenotype and IIM subtype
expected of that MSA. True positive MAAs were defined
as those in patients diagnosed with either CTD or IIM
phenotypes expected of that MAA. Otherwise, results
were deemed to be false positives. For patients with mul-
tiple MSAs, that which best reflected the clinical pheno-
type was assigned true positive, as MSAs are generally
mutually exclusive [8]. Additional MSAs in such cases
were false positives, except for anti-Mi2A and anti-Mi2B
(isoforms of the same Ab) where simultaneous true posi-
tives were accepted [22, 23]. All negative results were
deemed true negatives. In cases of uncertainty, an im-
munologist (SE) reviewed the source data to ensure
accuracy.
Statistics
Analysis was performed with STATA version 14 (Col-
lege Station, USA). Descriptive statistics examined char-
acteristics of different groups according to Ab status.
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Categorical data were summarised as frequencies and
proportions. Continuous data were summarised using
means and standard deviations. For individual Abs, the
rate of true and false positivity and the associated speci-
ficity for the presence of a consistent diagnosis or dis-
ease subtype was calculated. Logistic regression was
performed to investigate factors associated with true




In total, 401 LIAs were performed in 394 patients. Clin-
ical data were missing for 55 cases and duplicate testing
occurred in 7 patients (Fig. 1). Of the remaining 342,
IIM was diagnosed in 67/342 (19.6%) patients, CTD
without myositis in 120/342 (35.1%) patients, and non-
CTD/IIM in 155/342 (45.3%) patients (Table 1).
Autoantibody profiles in IIM patients: Most weak positive
MSAs were false positives
At least 1 Ab was detected in 42/67 (62.7%) IIM patients
(Table 2). Their clinical phenotypes included DM (n =
11), IMNM (n = 11), ASS (n = 7), clinically amyopathic
dermatomyositis (n = 4), PM (n = 4), and IBM (n = 2). In
these 42 patients, a total of 71 Abs were detected (21 pa-
tients had multiple Abs; Fig. 2). 50/71 (70.4%) Abs were
strongly positive (21 MSAs, 29 MAAs), and the majority
of these were true positives (48/50 [96.0%]). 2/50
strongly positive Abs were false, and both were MSAs
(anti-PL7 and anti-SAE1). Both patients had ASS and
each had another concurrently detected MSA that was
deemed to be the true positive. There were 21/71
(29.6%) weak positive Abs (7 MSAs, 14 MAAs). Of
these, 15/21 (71.4%) were true positives (3 MSAs, 12
MAAs) and 6/21 (28.6%) were false positives (4 MSA, 2
MAAs).
Seven IIM patients had apparent dual MSA positivity.
3/7 (43.0%; DM (n = 2) and OM (n = 1)) had concurrent
anti-Mi2A and anti-Mi2B. 1/7 (14.3%; ASS (n = 1)) was
strongly positive for both anti-EJ and anti-PL7; anti-EJ
was deemed the true positive based on significantly
higher signal intensity when reviewed with the source
data compared to anti-PL7 which just met the cut off for
a strong positive result. Another was strongly positive
for both anti-Jo1 and anti-SAE1; anti-Jo1 was felt to be
the true positive as the patient clinically had ASS. 2/7
(28.6%) patients had dual weak false positives (anti-
MDA5 and anti-TIF1γ in a patient with OM; anti-SAE1
and anti-SRP in a patient with PM).
Autoantibody profiles in CTD patients without myositis:
False positive MSAs are detected commonly
At least 1 Ab was detected in 41/120 (34.2%) patients
with CTD without myositis (Fig. 2 and Table 2). Sys-
temic sclerosis was the most common diagnosis. A total
Fig. 1 Study population categorised by final diagnoses and total number of Abs detected in each group
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of 61 Abs were detected these 41 individuals with 31/61
(50.8%) being strongly positive; 24/31 (77.4%) of these
were true strong positives, and all were MAAs (anti-Ro52
[n = 20], anti-PMScl100 [n = 1], anti-PMScl75 [n = 1],
anti-Ku [n = 2]). Of the strong false positive Abs (n = 7), 5
were MSAs (n = 1 for each of anti-EJ, anti-Mi2A, anti-
SAE1, anti-SRP, anti-PL12), and 2 were MAAs (anti-Ku in
a patient with resolved undifferentiated connective tissue
disease and anti-PM-SCL75 in a patient with systemic
lupus erythematosus).
Weakly positive Abs were more common in CTD pa-
tients without myositis (30/61 [49.1%]; 13 MSAs, 17
MAAs) compared to IIM patients (21/71 [29.6%]; 7
MSAs, 14 MAAs; p = 0.02). 16/30 (53.3%) were true pos-
itives (all MAAs), and of the remaining false positives, 1
MAA and 13 MSA were detected (anti-SRP [n = 4], anti-
PL12 [n = 2], anti-PL7 [n = 2], anti-TIF1γ [n = 2], anti-Jo
[n = 1], anti-Mi2A [n = 1], and anti-OJ [n = 1]).
Four patients in the CTD group without myositis had
multiple MSAs. All were false positives, and all had an
anti-SRP (anti-SRP with anti-OJ, anti-SRP with anti-
PL12, anti-SRP with anti-EJ, and anti-SRP with both
anti-Mi2A anti-PL12).
Autoantibody profiles in non-IIM/CTD patients: Detection
of MSAs and MAAs is common
At least 1 Ab was detected in 38/155 (24.5%) non-IIM/
CTD patients with a total of 46 detected Abs in these 38
individuals (24 MSAs [52.2%], 22 MAAs [47.8%]) (Fig. 2
and Table 2). All were deemed to be false positive re-
sults. 17/46 (37.0%) Abs were strong positives and 7/17
(41.2%) of these were MSAs. The final diagnoses for the
6 patients with strongly positive MSAs deemed to be
false positives included immune checkpoint inhibitor re-
lated myofasciitis (n = 1; anti-EJ), genetic myopathy (n =
1; anti-Mi2B with anti-PL7), fibromyalgia (n = 1; anti-
Jo1), and unclear final diagnoses (n = 3; anti-Mi2B, anti-
TIF1γ, and anti-EJ).
29/46 (63.0%) Abs were weakly positive and 17/29 of
these were MSAs. In these, the final diagnoses were im-
mune checkpoint inhibitor related myofasciitis (n = 1;
anti-SRP), primary Raynaud’s phenomenon (n = 1; anti-
TIF1γ), fibromyalgia (n = 1; anti-Mi2B), statin-related
Table 1 Characteristics of study population
Number of patients
Total 342
Mean age in years (SD) 54 (14)
Female gender 222 (65%)
Pre-test working diagnosis
Suspected IIM 92 (26.9%)
CTDs without IIM 137 (40.1%)
Myopathic syndromes with low likelihood of IIM 113 (33.0%)







Inclusion body myositis 5
Immune mediated necrotizing myopathy 4
CTD without IIM 120 (35.1%)
Systemic sclerosis 91
Undifferentiated CTD 10





Other rheumatologic diagnoses 45
Other neurologic diagnoses 12
Genetic myopathy 11
Endocrinologic myopathy 5







SD standard deviation, IIM idiopathic inflammatory myopathy, CTD connective
tissue disease
Table 2 Cases of antibody positivity by final diagnosis
IIM 42/67 (62.7%)
Only weak MSA/MAA 9 (13.4%)
Only strong MSA/MAA 27 (40.3%)
Both weak and strong MSA/MAA 6 (9.0%)
CTD without IIM 41/120 (34.2%)
Only weak MSA/MAA 13 (10.8%)
Only strong MSA/MAA 18 (15.0%)
Both weak and strong MSA/MAA 10 (8.3%)
Non-IIM/CTD 38/155 (24.5%)
Only weak MSA/MAA 22 (14.2%)
Only strong MSA/MAA 13 (8.4%)
Both weak and strong MSA/MAA 3 (1.9%)
Any positive MSA/MAA across all diagnostic groups 121 (35.4%)
IIM idiopathic inflammatory myopathy, CTD connective tissue disease, MSA
myositis-specific autoantibody, MAA myositis-associated autoantibody
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toxic myopathy (n = 1; anti-Mi2B with anti-SAE1), poly-
myalgia rheumatica (n = 2; anti-OJ, anti-PL7), familial
amyloidosis (n = 1; anti-SAE1), and unclear (n = 8; anti-
SRP [n = 3], anti-TIF1γ [n = 2], antiPL7 with anti-SRP
[n = 1], anti-Mi2A with anti-SRP [n = 1], anti-PL12 with
anti-SRP [n = 1]).
Apparent dual positive MSAs were seen in 4 cases:
anti-SRP with anti-PL12, anti-SRP with anti-Mi2B, anti-
Mi2B with anti-SAE1, and anti-PL7 with anti-Mi2B.
Factors associated with true and false positive antibody
results
Weakly positive MSAs are often false positives
Across all diagnostic groups, weak positive MSAs were
more likely to be false positives than true positives (34/
37 [91.9%] false positives vs. 3/37 [8.1%] true positives),
although the same was not true for weak positive MAAs
(15/43 [34.9%] false positives vs. 28/43 [65.1%] true posi-
tives). This contrasts with strongly positive results,
where the majority were true positives (19/33 [57.6%]
true positives for MSAs, 53/65 [81.5%] for MAAs).
All weak positive anti-SRP (n = 10), anti-TIF1γ (n = 6),
anti-SAE1 (n = 3), anti-PL7 (n = 3), anti-OJ (n = 2), anti-
Mi2B (n = 2), anti-Jo1 (n = 1), and anti-MDA5 (n = 1)
were false positives. For anti-PL12, false weak positivity
was found in 4/5 (80.0%) cases. Amongst MAAs, false
weak positives were found in 3/4 (75.0%) cases of anti-
Ku and 6/14 (42.9%) cases of anti-Ro52. Anti-PM-Scl100
and anti-PM-Scl75 appeared to perform better with false
weak positives only in 1/7 (14.3%) cases and 5/18
(27.8%) cases, respectively.
Patterns of anti-PM-Scl100 and − 75 positivity
There were 7 patients with dual positivity for anti-PM-
Scl100 and anti-PM-Scl75, and all were true positives.
Three cases had dual weak positive results and 4 had
dual strong positive results. Four of these cases occurred
in IIM patients with OM (scleromyositis) and 1 with
amyopathic DM. The remaining 2 occurred in systemic
sclerosis patients without myositis. Anti-PM-Scl100 oc-
curred independently of anti-PM-Scl75 in 5 cases, 4 of
which (80.0%) were true positives. Anti-PM-Scl75, how-
ever, occurred independent of anti-PM-Scl100 in 19
cases where 12/19 (63.2%) were true positives.
Sensitivity, specificity, and factors associated with a positive
result
When considering individual Abs, specificity for the
presence of a consistent diagnosis or disease subtype
was generally high across all Abs (98.2–100.0% for weak
positives and 97.5–100.0% for strong positives; Supple-
mentary Table 1). However, weak positive anti-SRP had
the lowest specificity (97.0%). A pre-test working diagno-
sis of IIM and a strong positive Ab result were signifi-
cantly associated with true positivity (OR 50.8, 95%CI
13.66–189.22, p < 0.001 and OR 4.38, 95%CI 2.32–8.26,
p < 0.001, respectively) (Table 3).
Fig. 2 Categorisation of autoantibodies by final diagnosis, subtype, and strength of result
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Discussion
This study evaluated the clinical performance of the
EUROIMMUN Inflammatory Myopathies 16 Ag LIA, a
commonly used commercial assay. It is also the largest
to report factors associated with true positive results.
We showed that in expert-diagnosed IIM cases, 62.7% of
patients had at least 1 identified Ab on LIA. A strong
positive result and a high pre-test diagnosis of IIM was
most associated with true positive results. This empha-
sises the value of an expert clinician’s initial impression
in reaching an IIM diagnosis and that LIA testing for
IIM should be applied with caution in patients with low
diagnostic suspicion for IIM.
A weak positive MSA was much more likely to be a
false positive across all diagnostic groups (34/37 [91.9%]
false positives vs. 3/37 [8.1%] true positives). This was
particularly true for weakly positive anti-SRP results
which were all false positives in our study. Our study is
in agreement with other recent publications which have
also demonstrated that weak positives are more likely to
be false [24]. Whilst weak positive MSAs were more
likely to be false positives, specificity was high. Weak
positive anti-SRP had the lowest specificity. Our results
suggest that this LIA’s accuracy may be improved if the
threshold for defining weak positivity was increased, al-
though this may vary according to each antibody on the
assay [25].
We also found only 4/67 (5.9%) IIM cases with
multiple MSAs (excludes concurrent anti-Mi2A and
anti-Mi2B, isoforms of Mi2 autoantibodies which co-
exist frequently [23]). Two of these cases only had 1
true MSA each and in the other 2 cases, all were
false positive results. This is congruent with recent
large cohort studies demonstrating mutual exclusivity
of MSAs in IIM individuals [8] and highlights that
when multiple MSAs are found in LIA testing, results
should be treated with suspicion. Dual positivity for
the MAAs anti-PM-Scl100 and anti-PM-Scl75, in con-
trast, improved the reliability of the results in both
IIM and CTD without IIM cases.
Another notable finding was that a high proportion of
IIM patients were seronegative (37.3%). This number is
comparable to recent findings from a large cohort of
European IIM patients which found 38.3% of their cases
to be seronegative [8]. A growing number of Abs
currently not available in this LIA may be useful in the
correct clinical context. For example, in addition to anti-
HMGCR, recent larger cohorts of IIM demonstrate that
other emerging Abs such as anti-KS and anti-Zo are also
useful in the diagnosis of IIM [8] .
Limitations of this study include data drawn from a
single centre, although they represent a population of
nearly 3 million people. Secondly, data were analysed
retrospectively, and no specific additional review or tests
were performed to confirm the diagnostic categorisation.
Of the patients without CTD or IIM, most had at least
3 years of follow-up in their case notes, but it remains
possible that positive Ab results may represent preclin-
ical IIM or CTD. Additionally, negative Ab results were
assumed to be true negatives. It is possible that some
seronegative patients have detectable Abs via another
method such as immunoprecipitation or have a hitherto
undescribed Ab. Additionally, in cases where duplicate
testing on the same patient occurred, we included only
the most recent results. There is some evidence that cer-
tain MSAs might be lowered with treatment [26] so in-
cluding only the most recent LIA result may have
affected our results. However, clinicians seldom use the
LIA for disease monitoring and the seven duplicates
which occurred were more likely to be cases where the
accuracy of first LIA test was in question. Finally, the
final diagnoses made by the treating physicians could
have been biased by the Ab results. However, most pa-
tients had several years of follow-up allowing for their
diagnoses to be confirmed or reclassified over time and
these final diagnoses were used in this study.
Conclusions
MSAs and MAAs are increasingly gaining importance in
the diagnostic workup and management of IIMs.
Table 3 Associations between true positive myositis-specific and myositis-associated autoantibodies and clinical factors
Factor Any true positive MSA/MAA Any false positive MSA/MAA OR P CI
Female gender 78% (80/103) 67% (50/75) 1.74 0.10 0.89–3.39
Mean age of onset (SD) 50 (13) 52 (15) 0.99 0.35 0.96–1.01
Pre-test working diagnosis of IIM 59% (61/103) 19% (14/75) 50.8 <0.001 13.66–189.22
Biopsy in keeping with inflammatory myopathy 50% (7/14) 28% (7/25) 2.57 0.18 0.66–10.06
Myopathic EMG changes 64% (21/33) 43% (12/28) 2.33 0.11 0.83–6.54
Highest recorded CK (mean, SD) 1377 (3502) 563 (910) 1.0 0.108 1.00–1.00
Strong positive antibody result 70% (72/103) 35%
26/75
4.38 <0.001 2.32–8.26
MSA myositis-specific autoantibody, MAA myositis-associated autoantibody, OR odds ratio, P p-value, CI confidence intervals, SD standard deviation, IIM idiopathic
inflammatory myopathy, EMG electromyography, CK creatine kinase
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Clinicians may rely on commercially available LIAs to
identify these Abs. This study describes the clinical utility
of a widely used LIA and is the largest to report factors as-
sociated with true positive results. We demonstrated that
strongly positive autoantibodies and a high pre-test likeli-
hood of IIM are associated with true positive results on
LIA. Specificity for individual MSAs on the LIA for IIM is
high. Weak positive MSA results are more likely to be
false than true positives. Our data suggests that cut-off
values of the LIA may need to be redefined to increase its
accuracy. Our work adds to the understanding of the
increasing role of LIA testing for MSAs and MAAs in rou-
tine clinical practice and will support clinicians in under-
standing the relevance and implications of results.
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